Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Receivables (2021 - 2025)

Apellis Pharmaceuticals has reported Receivables over the past 5 years, most recently at $366.7 million for Q4 2025.

  • Quarterly results put Receivables at $366.7 million for Q4 2025, up 36.1% from a year ago — trailing twelve months through Dec 2025 was $366.7 million (up 36.1% YoY), and the annual figure for FY2025 was $366.7 million, up 36.1%.
  • Receivables for Q4 2025 was $366.7 million at Apellis Pharmaceuticals, up from $352.1 million in the prior quarter.
  • Over the last five years, Receivables for APLS hit a ceiling of $366.7 million in Q4 2025 and a floor of $719000.0 in Q2 2021.
  • Median Receivables over the past 5 years was $172.0 million (2023), compared with a mean of $152.0 million.
  • Biggest five-year swings in Receivables: soared 2191.12% in 2023 and later decreased 28.75% in 2025.
  • Apellis Pharmaceuticals' Receivables stood at $10.1 million in 2021, then dropped by 9.49% to $9.1 million in 2022, then soared by 2191.12% to $209.5 million in 2023, then grew by 28.64% to $269.5 million in 2024, then skyrocketed by 36.1% to $366.7 million in 2025.
  • The last three reported values for Receivables were $366.7 million (Q4 2025), $352.1 million (Q3 2025), and $220.1 million (Q2 2025) per Business Quant data.